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1. Introduction 
In the last few years, it has become evident that the immunological component is of central 
importance in Parkinson’s Disease (PD) pathogenesis and progression. This can also 
certainly be said about the prominent role that the protein -synuclein (Syn) is currently 
believed to play in the pathobiology of this neurodegenerative disorder. Moreover, the 
multiple mechanisms through which Syn might be affecting the immune system appear 
not to be just a consequence of disease progression, but to actively contribute to the delicate 
balance between neuroprotection and neurotoxicity that ultimately underlies a given stage 
of disease.  
PD is a proteinopathy, whose pathological hallmark is the presence of deposits of 
aggregated Syn in intracellular fibrillar inclusions in neurons of the substantia nigra pars 
compacta (SN) of the brain, known as Lewy bodies (LB) (Croisier et al., 2005; Spillantini et al., 
1998), and the loss of dopaminergic neurons (Braak et al., 2003). Three missense mutations, 
A53T, A30P and E46K, as well as multiple copies of the wild-type (Wt) Syn gene, are 
linked to early-onset, familial PD (Gasser, 2005; Kruger et al., 1998; Polymeropoulos et al., 
1997; Zarranz et al., 2004). Given that Syn is the major component of LB in both familial 
and sporadic PD cases (Spillantini et al., 1998), Syn is considered a critical factor in PD 
aetiology. Currently, the cellular and molecular mechanisms underlying the pathological 
actions of Syn are poorly understood, and the factors contributing to sporadic PD, 
representing the vast majority of PD cases, are not known. 
Syn, together with - and -synucleins, belong to the family of synucleins, a group of 
closely related, brain-enriched proteins. This 140 aa-residue protein is largely located in 
neuronal presynaptic terminals (Kim et al., 2004b) and in the nucleus (Yu et al., 2007). In 
particular, it is found in the neocortex, hippocampus and SN (Kim et al., 2004b), and in other 
brain regions, as well as within astrocytes, microglia and oligodendroglia (Austin et al., 
2006; Mori et al., 2002; Richter-Landsberg et al., 2000). It is known to interact with a variety 
of proteins (Jenco et al., 1998; Peng et al., 2005) and lipid membranes (Jo et al., 2000). The 
physiological functions of Syn are still being established, but its interaction with pre-
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synaptic membranes and lipids suggests a role in the regulation of synaptic vesicle pools 
including dopamine release control (Perez & Hastings, 2004) and in lipid metabolism (Cabin 
et al., 2002; Castagnet et al., 2005; Golovko et al., 2009).  
Both in vitro and in vivo in LB, Syn can self-assemble to form ordered fibrillar aggregates, 
characterized by a cross -sheet structure, that are morphologically similar to the amyloid 
fibrils found in neuritic plaques in Alzheimer´s disease (AD) as well as in deposits 
associated with other amyloidogenic processes (Chiti & Dobson, 2006). The initial phase of 
the aggregation process is thought to involve the formation of intermediate oligomers and 
protofibrillar species which, according to accumulating experimental evidence, can be more 
toxic to cells than the mature fibrils into which they develop (Bucciantini et al., 2002; Stefani 
& Dobson, 2003). These and other findings suggest a common structure-linked toxicity 
among pre-fibrillar species, and propose similar mechanisms contributing to pathogenesis 
for this group of diseases (Baglioni et al., 2006; Bucciantini et al., 2004). Overall, different 
hypotheses have been proposed that postulate that Syn induces a ‘gain of toxic function’ 
upon aggregation (Bennett, 2005).  
While Syn is typically considered as an intracellular protein, it has also been found to be 
normally present in extracellular biological fluids, including human cerebrospinal fluid 
(CSF) and blood plasma (Borghi et al., 2000; El-Agnaf et al., 2003; El-Agnaf et al., 2006; Lee et 
al., 2006; Tokuda et al., 2006). However, Syn levels have been found to be elevated in 
plasma from PD and multiple system atrophy (MSA) patients relative to age-matched 
controls (Lee et al., 2006), while lower levels than normal have been detected in CSF from 
PD patients (Tokuda et al., 2006). On the other hand, two studies by El-Agnaf and 
colleagues showed an elevated content of oligomeric Syn spedies present in plasma (El-
Agnaf et al., 2006) and post mortem CSF (Tokuda et al., 2010) from PD patients, compared to 
controls, indicating that changes in the levels and characteristics of extracellular Syn are 
associated with the disease (Lee, 2008). Even though membrane permeability from dying 
cells could be one contributing factor, it has been suggested that vesicle-mediated exocytosis 
from normal cells is probably the main source of extracellular Syn (Lee, 2008). By using 
brain homogenates and neuronal cell cultures, Lee and colleagues (Lee et al., 2005) have 
shown that both monomeric and aggregated Syn can be secreted by an unconventional 
secretory pathway. On the other hand, extracellular Syn has been shown to be taken up by 
neuronal and microglial cells in culture, although the nature of the mechanism involved is 
still controversial (Lee, 2008). In addition, two recent studies have provided strong evidence 
for a neuron-to-neuron and neuron-to-non-neuronal cell transmission of Syn aggregates 
and their associated cytotoxicity, in cellular and mouse models of PD (Danzer et al., 2011; 
Desplats et al., 2009), highlighting the importance of extracellular Syn in the pathogenic 
mechanism of -synucleinopathies. 
2. Neuroinflammation in PD 
Another prominent pathological feature of PD brains is the presence of a robust 
inflammatory response mediated by activated microglia and reactive astrocytes in affected 
areas of the SN (Glass et al., 2010). Inflammation is the first response of the immune system 
to pathogens or irritation. In acute conditions, it protects tissue against invading agents and 
promotes healing. However, a chronic inflammatory state can turn harmful towards the 
host´s own tissue (Gao & Hong, 2008; Kim & Joh, 2006). Microglia are the resident 
immunocompetent cells in the brain (Aloisi, 2001), capable of antigen presentation to 
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lymphocytes (Kreutzberg, 1996) and rapid activation in response to immune insults and 
invading of PD pathogenesis in the central nervous system (CNS) (Kim & Joh, 2006). As a 
result of pathogen invasion or tissue damage, microglia switch to an activated phenotype 
and thereby promote an inflammatory response that serves to further engage the immune 
system by recruiting other cells to the site of brain lesion, and initiate tissue repair (Glass et 
al., 2010). However, uncontrolled inflammation may result in production of neurotoxic 
factors that can be highly detrimental (Gao & Hong, 2008; Glass et al., 2010). Indeed, 
inflammation in the CNS and sustained overactivation of microglia, i.e. reactive 
microgliosis, are currently believed to be actively involved in the pathogenesis of various 
neurodegenerative diseases including PD, AD, multiple sclerosis (MS), and amyotrophic 
lateral sclerosis (ALS) (Gao & Hong, 2008; Glass et al., 2010; Kim & Joh, 2006; Long-Smith et 
al., 2009). 
At present, whether microglial activation ultimately protects or actually exacerbates 
neuronal loss in the context of PD and other related diseases is still under debate (Delgado 
& Ganea, 2003; Gao & Hong, 2008; Halliday & Stevens, 2011; Sanchez-Pernaute et al., 2004; 
Vila et al., 2001; Wu et al., 2002; Wyss-Coray & Mucke, 2002), although the current view 
favours the second hypothesis. Evidence of microglial attack in PD is supported by findings 
from epidemiological studies, animal models, and cell culture experiments (McGeer & 
McGeer, 2008). Epidemiological studies have revealed that taking ibuprofen anti-
inflammatory agent regularly is associated with a 35% lower risk of PD (Chen et al., 2005; 
Chen et al., 2003), supporting the concept that inflammatory attack is contributing to 
dopaminergic neuronal loss. On the other hand, in vivo studies show that the specific early 
up-regulation of SN microglia in PD correlates with disease severity and dopamine terminal 
loss (Orr et al., 2005; Ouchi et al., 2005). Overall, studies based on animal models and in vitro 
cell culture, indicate that dopaminergic cells are highly sensitive to inflammatory attack 
(Castano et al., 1998; Fernagut & Chesselet, 2004) and that microglial cells can be strongly 
activated to mount such an inflammatory response (Austin et al., 2006). Moreover, it has 
been recently reported that treatment with CSF from PD patients strongly affects cultured 
microglial cells, resulting in reduced cell growth, morphological changes, as well as 
increased content and aggregation of Syn (Schiess et al., 2010). This illustrates how 
microglia itself, and not only dopaminergic neurons, can be highly affected by the medium 
in a PD scenario. 
3. Syn-induced microglial activation 
The results gathered thus far using the different PD animal models have substantially 
increased our understanding of PD’s pathogenesis by usually providing different but 
probably complementary information. Thus, while the MPTP mouse model of PD indicates 
that inflammation in the SN can be self-propagating and leads to progressive 
neurodegeneration, the Syn transgenic animal model demonstrates that overexpression of 
this endogenous protein can certainly provide a powerful source of inflammation (McGeer 
& McGeer, 2008). Whether microglial activation is essentially caused by the release of 
aberrant Syn species to the extracellular space, (Reynolds et al., 2008b; Wersinger & Sidhu, 
2006; Zhang et al., 2005), or otherwise, that neuronal death itself drives microglial immune 
responses in an Syn-independent manner (Giasson et al., 2000; Mandel et al., 2005; 
Przedborski et al., 2001), is still under debate. However, there is ample accumulated 
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evidence pointing at Syn as the main trigger of microglial activation in PD (Roodveldt et 
al., 2008). For example, several studies have demonstrated that extracellular and nigral 
Syn- containing aggregates are often surrounded by activated microglia or inflammatory 
mediators in PD brains (McGeer et al., 1988; Yamada et al., 1992), similarly to what has been 
described for amyloid plaques in AD (Griffin et al., 2006). Moreover, the extent of microglial 
activation in the SN from PD patients has been found to be correlated with the degree of 
Syn accumulation (Croisier et al., 2005) and with increased Syn levels as evidenced by in 
vitro (Kim et al., 2009; Klegeris et al., 2008) and in vivo (Lee et al., 2009a) studies, strongly 
supporting the view that the protein has a major role in phenotypic changes of microglia. 
Up to this point, a considerable number of in vivo studies with animal models of PD that 
directly link Syn with microglial activation have been reported. It has been demonstrated 
in mice that overexpression of Syn alone (by using adeno-associated virus, AAV) is 
sufficient to trigger neuroinflammation, involving not only classical microglial activation 
but also stimulation of adaptive immunity, preceding the appearance of overt 
neurodegeneration signs (Theodore et al., 2008). In line with this finding, a rat AAV-based 
model for overexpressing the A53T Syn variant in the SN revealed dramatic changes in 
cytoskeletal protein levels and activated microglia-mediated neuroinflammation in the 
striatum (with increased release levels of IL-1, IFN-, and TNF- proinflammatory 
cytokines), well before neuronal loss was evident (Chung et al., 2009). Another recent study 
using a AAV rat PD model showed that overexpression of Wt Syn in the SN not only leads 
to persistent microglia activation, but that depending on the degree of Syn-induced 
neurophatology that models either the onset or the late stages of the disease, different 
microglial responses will occur: upon lower Syn expression levels where only 
neurodegeneration occurs, microglia with antigen-presenting capabilities predominate, 
whereas levels that can induce neuronal cell death correlate with long-term induction of 
macrophagic microglia (Sanchez-Guajardo et al., 2010), suggesting that microglia may play 
different roles during disease progression (Sanchez-Guajardo et al., 2010). 
Two recent studies have explored the link between neuroinflammation and Syn 
dysfunction by lipopolysacharide (LPS) injection in rat (Choi et al., 2010) or mice (Gao et al., 
2011), to trigger systemic and brain inflammation. In the first study, the authors observed 
increased microglia activation and secretion of proinflammatory cytokines as well as greater 
nitration of proteins including Syn, in elderly rats, suggesting that an exaggerated 
neuroinflammatory response that occurs naturally with aging might contribute to Syn 
aggregation and dopaminergic neurodegeneration in PD (Choi et al., 2010). In the second 
study, the authors evaluated dopaminergic neurodegeneration, Syn pathology and 
neuroinflammation in Wt and transgenic A53T Syn-overexpressing mice (Gao et al., 2011). 
They observed that, while both models initially displayed acute neuroinflammation, only 
the latter developed persistent neuroinflammation together with chronic progressive 
degeneration of nigrostriatal dopamine pathway, accumulation of aggregated, nitrated 
Syn, and formation of LB (Gao et al., 2011), suggesting that genetic factors and 
environmental exposures act synergistically to precipitate the development of PD. On the 
other hand, microglial cells from Syn-knockout mice have been shown to exhibit a 
remarkably different morphology compared to Wt cells (Austin et al., 2006), displaying 
elevated levels of secreted pro-inflammatory cytokines such as TNF- and IL-6 after 
activation, indicating that Syn plays a critical role in modulating the microglial activation 
state. More recently, the authors have found that microglial activation in this model is 
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accompanied by increased protein levels of three enzymes involved in lipid-mediated 
signalling, which suggests a broader function for Syn in brain physiology beyond synapsis 
control (Austin et al., 2011). 
In the last few years, several in vitro studies have focused on the effects of extracellular Syn 
on microglial activation. Zhang et al. (Zhang et al., 2005) first reported that exogeneous, 
aggregated Syn cause activation of microglial cells, which then become toxic towards 
cultured dopaminergic neurons. Their results indicate that microglial phagocytosis of Syn 
and activation of NADPH oxidase, are critical in Syn-induced microglial activation and 
neurotoxicity. This finding is highly relevant considering that aggregated Syn has been 
shown to be secreted by exocytosis  from neuroblastoma and primary neuronal cells 
(Danzer et al., 2011; Lee et al., 2005), and by stressed neurons (Klegeris et al., 2008). 
Moreover, following the discovery that Syn aggregates can be released from neurons and 
transmitted to neighbouring cells (Desplats et al., 2009), a study has recently shown that 
Syn release by SH-SY5Y neuroglioma cells, especially when treated with MPP+ neurotoxin, 
are able to activate the inflammatory response in a microglial cell line (Alvarez-Erviti et al., 
2011). 
Up to this point, research on Syn-mediated cell response has focused primarily on the 
effects on neuroinflammation (Benner et al., 2008) or microglial activation (Cookson, 2009; 
Reynolds et al., 2008a; Thomas et al., 2007; Zhang et al., 2007; Zhang et al., 2005) of Syn in 
its aggregated form. Interestingly, Reynolds and coworkers (Reynolds et al., 2008b) have 
found that nitrated, aggregated Syn (N-Syn) has a stronger stimulating effect on 
microglia than that of nitrated but non-aggregated Syn. In addition, several investigations 
have found that N-Syn, which has been detected in LB of human brains with PD (Giasson 
et al., 2000) and has been linked to neurodegeneration in PD mouse models (Benner et al., 
2008; Gao et al., 2008), induces a neurotoxic inflammatory microglial phenotype that 
accelerates dopaminergic neuronal loss (Biasini et al., 2004; Thomas et al., 2007; Zhang et al., 
2005; Zhou et al., 2005). By integrating genomic and proteomic techniques, Gendelman and 
colleagues  created a fingerprint of microglial cell activation following its interactions with 
aggregated N-Syn in cell culture (Reynolds et al., 2008a), indicating that the activation, 
which was found to be capable of mediating dopaminergic neurotoxicity, is mainly 
mediated by the NF-B pathway (Reynolds et al., 2008a). However, whether extracellular 
Syn contains the same modifications than the protein found in LB (Anderson et al., 2006; 
Giasson et al., 2000; Hodara et al., 2004), which is a typically pro-oxidative environment, is 
still uncertain (Lee, 2008).  
Over the last few years, certain differential functions for non-aggregated, extracellular aSyn 
in glia have been reported. It has been observed that, in contrast to the aggregated form, 
monomeric Syn enhances microglial phagocytosis (Park et al., 2008). A few investigations 
that explore the effects of non-aggregated Syn on the cytokine release profile of potentially 
relevant cells have been recently done using monocytic (Klegeris et al., 2008) or macrophage 
(Lee et al., 2009b) cell lines, and primary astrocyte (Klegeris et al., 2006) or microglial 
(Roodveldt et al., 2010; Su et al., 2009; Su et al., 2008) cultures. Indeed, we have observed a 
strong innate immune response in primary glial and microglial cell cultures elicited by 
exogenous, non-aggregated Syn (Roodveldt et al., 2010). Interestingly, a comparative study 
using unmodified aSyn has recently shown that exogenous non-aggregated Syn induces 
higher TNF-, IL-1 and ROS release levels than aggregated Syn in microglia (Lee et al., 
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2010). These and other recent findings point at the importance of exploring the effects on the 
immune response of aggregated as well as non-aggregated Syn.  
Even though a study using monocytic THP-1 cell line (Klegeris et al., 2008) had shown 
modest increases in IL-1 and TNF- secretion levels after stimulation with A30P, A53T, or 
E46K Syn mutants compared to the Wt protein, there is a lack of a comprehensive study of 
the effect exerted by non-aggregated Syn, performed with primary cell cultures. With this 
in mind, we analysed the cytokine release profile of primary microglial cultures ―which 
represesnts a more comparable physiological environment― after stimulation with Wt or the 
PD-linked Syn mutants (Roodveldt et al., 2010). Indeed, we found remarkable differences 
between the Syn variants in the interleukin and chemokine release profiles and significant 
effects on the microglial phagocytic capacity (Roodveldt et al., 2010). In particular, we 
observed marked differences in IL-6 and IL-1pro-inflammtory cytokines, IL-10 
immunoregulatory cytokine, as well as IP-10/CXCL10, RANTES/CCL5, MCP-1/CCL2 and 
MIP-1/CCL3 chemokines release levels. Our results indicate that extracellular, non-
aggregated Wt Syn produces a moderate to low pro-inflammatory response in glia, 
together with a reduction of the immunoregulatory response, and a moderate stimulation of 
Th1 chemokine secretion. The A30P and E46K pathological variants, on the other hand, can 
induce strong pro-inflammatory and immunoregulatory responses, together with marked 
increases in chemokine release levels. This exacerbated innate immune response might 
explain the earlier onset and more rapid evolution of these two genetic cases of PD as 
compared to the sporadic kind. Intriguingly, our results from the pathologically-linked 
A53T variant showed not to provoke a significant innate immune response, which might 
suggest that other neurodegeneration mechanisms contributing to the pathogenesis of PD, 
probably involving the adaptive immune response, might exist in this case. Combined with 
the effect on microglial phagocytosis, our results indicate that these Syn-induced 
phenotypes might reflect either a classical (A30P and E36K) or an alternative (A53T) 
microglial activation state, or a hybrid phenotype (Wt), which could  probably explain the 
different disease progression modes that can occur in PD. Alternative activation of 
macrophages and microglia is a response to tissue injury that is thought to be involved in 
tissue repair and restoration (Ponomarev et al., 2007), and has been suggested to play a role 
in repair and extracellular matrix remodelling  in AD (Colton et al., 2006). Currently, there is 
no other indication that such an activation mode could be operating in the context of PD. 
Upon activation, microglia and astrocytes start secreting inflammatory cytokines in order to 
communicate and mount the immune response to counteract disease or injury. The 
cytokines TNF-, IL-1, IL-2, IL-4, IL-6, TGF-, TGF-1, TGF-2 have all been reported to be 
increased in the nigrostriatal region and CSF of patients with PD or DLB (Croisier & 
Graeber, 2006). As a result of Syn-induced activation of microglia in vitro, a few cytokines 
and metabolites have been shown to be significantly up-regulated (reviewed in (Roodveldt 
et al., 2008)): IL-6, IL-1, ICAM-1, TNF-, IFN- MCP-1, O2-, iROS, and PEG2, glutamate, 
and iCys. In general, disease-linked Syn variants show a stronger effect on cytokines 
release than does the Wt protein. Interestingly, analysis of the microglia transcriptome by 
Gendelman and coworkers (Reynolds et al., 2008a) after stimulation with aggregated N-
Syn, revealed a significant up-regulation of the toll-like receptor 2 (TLR-2) gene. TLRs are 
known to sense the molecular signatures of microbial pathogens, and play a fundamental 
role in innate immune responses, inducing the expression of diverse inflammatory genes 
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(Kawai & Akira, 2007). Therefore, it seems plausible that cells challenged with Syn, or with 
certain forms of Syn, could become hyper-responsive to inflammatory signals. 
Activated microglia can also produce substantial amounts of superoxide radicals, which 
may be the major source of the oxidative stress thought to be largely responsible for 
dopaminergic cell death in PD. The generation of ROS by microglia activated by Syn 
(Thomas et al., 2007) can result in oxidation and nitration of proteins, DNA modifications, 
and lipid peroxidation, leading to neurotoxicity (Zhang et al., 2005). Oxidation (Ko et al., 
2000; Souza et al., 2000) and nitration (Giasson et al., 2000; Souza et al., 2000) of Syn, in 
turn, can lead to the formation of more aggregates, which could result in increased cytotoxic 
effects. Consistent with this, Kelly et al. have shown that high levels of oxidized cholesterol 
metabolites in brains from PD and dementia with LB patients, accelerate Syn fibrillation 
(Bosco et al., 2006). On the other hand, McGeer and colleagues (Klegeris et al., 2007a) have 
reported that Syn-stimulated microglia, in combination with IFN-, produce and increase 
in the toxicity on human monocytic cells exerted by neurotoxic secretions (Klegeris et al., 
2007a). Interestingly, this toxicity can be diminished with specific ligands for ryanodine 
receptors (Klegeris et al., 2007a), which are known to help mediate the efflux of Ca2+ ions 
from intracellular stores and avoid uncontrolled increases in [Ca2+]i  that may lead to cell 
death (Giorgi et al., 2008). 
Further insight into the mechanism of pathogenesis might derive from the findings that 
several proteins which are thought to be linked to PD are up-regulated as a result of Syn-
induced microglial activation. Gendelman and co-workers, by determining the activated 
microglia proteome profile (Reynolds et al., 2008a), found that aggregated N-Syn 
activation of microglia results in differential expression of several proteins. These range 
from proteins involved in oxidative stress, cell adhesion, glycolysis, growth control, and 
migration, to cytoskeletal proteins. It is worth noting that two of those proteins found to be 
most up-regulated, calmodulin and ubiquitin, have been shown to interact with Syn with 
possible functional consequences. Calmodulin has been shown, in vitro, to bind to Syn in a 
Ca2+-dependent manner (Lee et al., 2002) and to inhibit Syn fibrillation (Martinez et al., 
2003). On the other hand, a fraction of Syn found in LB is mono-ubiquitinated (Hasegawa 
et al., 2002; Tofaris et al., 2003), but the role of this modification remains unclear. Recently, it 
has been demonstrated that the ubiquitin-protein isopeptide ligase, seven in absentia 
homolog (SIAH), directly interacts with and monoubiquitinates Syn, promoting its 
aggregation (Lee et al., 2008; Rott et al., 2008) and apoptosis (Lee et al., 2008). In addition, 
there is also evidence implicating a role for the ubiquitin-proteasome system (UPS) in PD 
(reviewed in (Lim & Tan, 2007)). Also of interest are the elevated levels of Hsp70 observed 
upon microglial activation. This central chaperone has been demonstrated to inhibit Syn 
aggregation in vitro (Dedmon et al., 2005; Huang et al., 2006; Roodveldt et al., 2009), in 
neuroglioma cells (Klucken et al., 2004) as well as in fly (Auluck et al., 2002) and mouse 
(Klucken et al., 2004) models of PD, protecting cells from the cytotoxic effects of aggregates.  
4. Links between Syn and astrocytes and oligodendrocytes 
Together with microglial cells, astrocytes and oligodendrocytes are part of glia, which 
normally serve neuroprotective functions but, given adverse stimulation as discussed 
before, they may contribute to develop chronic neuroinflammation (Halliday & Stevens, 
2011; McGeer & McGeer, 2008). Compared to microglia, the functions of astrocytes are 
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poorly understood. Because they have been shown to produce both pro-inflammatory and 
anti-inflammatory agents, these cells are thought to have a dual role (McGeer & McGeer, 
2008). Many ICAM-1-positive astrocytes are seen in the SN of PD brains and this may attract 
reactive microglia to the area since microglia carry the counter receptor LFA-1 (Miklossy et 
al., 2006). Indeed, Syn has been shown to be capable of both of activating microglia and 
stimulating astrocytes to produce IL-6 and ICAM-1 (Klegeris et al., 2006). On the other hand, 
astrocytes have been shown to secrete a number of neurotrophic factors that protect 
dopaminergic neurons in some models of PD (McGeer & McGeer, 2008), but the 
mechanisms underlying most of these functions are not yet known. Astrocytes have been 
shown to express Syn (Tanji et al., 2001). Interestingly, the presence of Syn-containing 
inclusion bodies in astrocytes of sporadic PD brains has been observed (Braak et al., 2007; 
Terada et al., 2003; Wakabayashi et al., 2000). Finally, a recent study showed that astrocyte 
expression of A53T Syn leads to the development of progressed paralysis, strong 
microglial activation, and neurodegeneration (Gu et al., 2010). 
There is still little data on the role of oligodendrocytes in PD. Syn-containing inclusions 
have been detected in this cell type in MSA, in DLB, and in PD (Campbell et al., 2001; 
Wakabayashi et al., 2000). McGeer and colleagues have reported the presence of 
complement-activated oligodendrocytes in the SN of PD cases (Yamada et al., 1992). 
Intriguingly, transgenic mice overexpressing Wt Syn in oligodendrocytes have been 
observed to develop severe neurological alterations and neurodegeneration (Shults et al., 
2005; Yazawa et al., 2005), drawing the attention to a possible role of these glial cells in PD. 
5. Expression of Syn by immunocompetent cells 
Given that Syn expression has been reported also in non-neuronal cells, it is currently 
thought to play a role besides dopamine release control. While searching for a link between 
the CNS and peripheral immune system in PD, Kim et al. (Kim et al., 2004a) found that Syn 
was up-regulated in peripheral blood mononuclear cells (PBMC) at the gene level, in 
idiopathic PD vs. non-PD controls. Moreover, by in vitro transfection with Wt, A30P and 
A53T Syn genes, they found that Syn expression is correlated to glucocorticoid-sensitive 
apoptosis, possibly caused by the enhanced expression of glucocorticoid receptor (GR), 
caspase activation, CD95 (Fas) up-regulation, and ROS production. However, the increase in 
ROS production by overexpression of the Syn mutants was markedly greater than for Wt 
Syn. Syn expression has also been found in cultured human macrophages (Tanji et al., 
2002) and its expression levels have been reported to increase by stimulation with pro-
inflammatory cytokine IL-1or LPS (Tanji et al., 2002), further supporting a role for Syn in 
the inflammatory process. Finally, expression of Syn in cultured human T cells, B cells, 
natural killer (NK) cells and in monocytes/macrophages, have been reported (Shin et al., 
2000). Currently, it is not known whether expression or aggregation, of Syn in T cells can 
be regulated by ligand activation of the T cell. This may be relevant as it could represent a 
key link between regulation of the adaptive immunity and Syn expression levels. 
6. Syn and the adaptive immune response in PD 
In the last few years, mounting evidence has pointed at a possible participation of the 
adaptive immune system in PD pathogenesis. However, whether this immune response 
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actually contributes to neurodegeneration, and in that case by which mechanism, remains 
unknown. The initial observations in PD patients that a small amount of CD8+ T-
lymphocytes occur in proximity to degenerating nigral neurons (McGeer et al., 1988), and 
the occurrence in LB of components of the classical or antibody-triggered complement 
cascade (Yamada et al., 1992) had suggested a possible involvement of the adaptive 
immunity in the PD process. More recently, the finding of accumulated IgG in the SN of PD 
patients and increased expression of IgG-binding receptors on activated microglia (Orr et 
al., 2005), and the detection of anti-Syn autoantibodies (AAb) in blood serum of PD 
patients (Papachroni et al., 2007), suggest that the pathological process may involve 
adaptive immune-mediated mechanisms. In addition, the observation that humoral immune 
mechanisms can trigger microglial-mediated neuronal injury in animal models of PD (He et 
al., 2002), and the finding by Standaert and colleagues of IgG deposition in mouse brains  
following AAV-mediatedSyn overexpression in the SN (Theodore et al., 2008), further 
support a role of the adaptive immune system in disease progression.  
A possible consequence of the initial microglial activation in the affected regions of PD 
brains is the local permeabilization of the blood-brain barrier (BBB), leading to infiltration to 
the affected regions by B- and/or T-lymphocytes (Racke et al., 2000). Indeed, a remarkable 
T- and B-cell infiltration into the SN linked to Syn overexpression was observed at the 
early stages, i.e. before the appearance of significant dopaminergic neuronal loss, reaching 
levels in the SN of up to 10-fold and 5-fold compared to controls (Theodore et al., 2008). A 
recent study by Hunot and colleagues (Brochard et al., 2009) has shown that CD8+ and CD4+ 
T-cells, but not B-cells, had invaded the brain in PD patients and in MPTP-treated mice 
during the course of neural degeneration. Furthermore, based on these results the authors 
propose that T-cell dependant toxicity is essentially mediated by CD4+ T-cells and requires 
the expression of FasL (Brochard et al., 2009). Given that the FasL pathway had been shown 
to produce proinflammatory cytokine responses in macrophages (Park et al., 2003), the 
authors speculate that the CD4+ Th FasL-mediated activation of microglia could participate 
in neuroinflammation and neurodegeneration processes in PD (Brochard et al., 2009).  
Based on results obtained with an MPTP murine model of the disease, Gendelman and 
colleagues (Reynolds et al., 2010) have suggested that the Syn-specific regulatory T-cells 
(Treg cells), which are regulatory components of the adaptive immunity, might be able to 
counteract the autoaggresive effector T-cell responses that exacerbate neuroinflammation 
(Benner et al., 2008), and therefore contribute to attenuate neurodegeneration in PD. 
Indeed, the same group has reported that microglial cells stimulated with N-Syn are 
susceptible of essentially opposing immune regulatory responses by Treg cells (CD4+, 
CD245+) and effector T-cells (CD4+, CD25-) in culture (Reynolds et al., 2009a). By 
analysing an array of cytokines released by treated microglia, the authors found that, 
while the effector T-cell subset exacerbates microglial-mediated inflammation and may 
induce neurotoxic responses, Treg cells are able to suppress N-Syn microglial-induced 
reactive-oxygen species (ROS) and NF-B activation and are proposed to be 
neuroprotective (Reynolds et al., 2009a). Furthermore, the study indicates that Treg cells 
can regulate microglial inflammation by inducing Fas-FasL-mediated apoptosis of N-
Syn-stimulated microglial cells (Reynolds et al., 2009a). By using a proteomic analysis, 
the authors further showed that these Treg cells can significantly alter the microglial 
protein expression profile for certain proteins linked to cell metabolism, migration, 
protein transport and degradation, redox biology, and cytoskeletal and bioenergetic 
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metabolism, to presumably attenuate the neurotoxic phenotype caused by N-Syn 
stimulation (Reynolds et al., 2009b).  
Thus far, accumulated data demonstrate that in the MPTP model of PD, misfolded and 
aggregated Syn are secreted from neurons, which promotes pro-inflammatory M1-type 
microglia and cytotoxic T-cells, therefore amplifying neuronal damage. In sporadic human 
PD, it is currently unkown which factor triggers disease onset, but it has been proposed that 
under certain circumstances, a similar set of temporal and mechanistic events could 
transform neuroprotective microglia and T cells into cytotoxic cells, thereby accelerating 
disease progression (Appel et al., 2010). This way, activated microglia and the cytokine 
milieu that they generate might promote T-cell differentiation into different cell subsets in 
the context of PD (Appel et al., 2010). Indeed, it has been shown that M1 (pro-inflammatory) 
cells promote, whereas M2 (non-inflammatory) cells reduce, CD4+ Th1 cell proliferation and 
function (Verreck et al., 2004), but also that, conversely, T-cells can dictate microglial pro- or 
anti-inflammatory phenotypes (Giuliani et al., 2003; Kebir et al., 2007; Mount et al., 2007). 
Whether microglia dictate the specific T-cell phenotype or otherwise, that T-cells dictate the 
specific microglial phenotype (i.e. M1 vs. M2), is still unknown (Appel et al., 2010). But 
overall, the communication established between microglia, T cells and neurons seem to 
indicate that the immune response is not only a consequence of injury, but that it actively 
contributes to the balance between neuroprotection and neurotoxicity (Appel et al., 2010; 
Stone et al., 2009). 
To analyse the possibility that humoral immunity may play a role in initiating or regulating 
inflammation, Orr et al. (Orr et al., 2005) analysed the association between nigral 
degeneration and humoral immune markers in brain tissue of patients with idiopathic or 
genetic PD and controls. All the patients with PD revealed IgG, but not IgM, binding on 
dopamine neurons. Moreover, the proportion of IgG-immunopositive neurons showed a 
negative correlation with the degree of cell loss in the SN, and positive correlation with the 
number of activated microglia. IgG was found to be concentrated at the cell surface of 
neurons, but also on their LB, and was shown to co-localize with Syn. These results, in 
combination with their finding that activated microglia express high-affinity IgG receptors 
(FcRI) in both idiopathic and genetic forms of PD, might suggest that the activation of 
microglia may be induced by neuronal IgG (Orr et al., 2005).  
The question regarding the functional importance of antibodies against antigen-specific, 
disease-associated neuronal proteins still needs to be addressed. It has been demonstrated 
that an IgG fraction purified from serum of PD patients causes death of dopaminergic 
neurons in vivo following stereotaxic injection in the SN of experimental animals (Chen et 
al., 1998), and the presence of immunoglobulins in PD brain tissue have been proposed to 
lead to the targeting of dopaminergic nigral neurons for destruction (Orr et al., 2005). 
Currently, it remains unknown whether these anti-Syn AAb are neurotoxic, or on the 
contrary, they actually have a neuroprotective role, as has been shown in a human Syn 
transgenic mouse model of PD (Masliah et al., 2005).  
A recent study has assessed the presence of auto-antibodies (AAb) against all three 
synucleins in the peripheral blood serum of PD patients and healthy controls (Papachroni et 
al., 2007). While the presence of AAb against - and -Syn showed no association with PD, 
multi-epitopic AAb against Syn were detected in 65% of all patients, with a strong 
correlation with the inherited mode of the disease. In addition, a recent study based on 
measuring AAb levels against monomeric, oligomeric, and fibrillar Syn in serum from PD 
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patients (Gruden et al., 2011), showed that all three AAb specificities reached the highest 
values after 5-year of disease duration, and subsided in 10-year sufferers. Intriguingly, there 
was a ca. 15-fold increase in AAb titre values relative to monomeric Syn (72% of patients), 
and a ca. 4-fold increase for Syn oligomers (56% of patients). Moreover, the authors also 
found a decline in CD3+, CD4+ and CD8+ T-lymphocyte and B-lymphocyte subsets. Based 
on these results, they suggest that Syn toxicity elimination by AAb in early PD pathology 
might be linked with the decline of lymphocyte subsets reflecting the influence of 
inflammatory and oxidative stress processes (Gruden et al., 2011). 
Despite their potential involvement in PD pathogenesis and progression, the role of NK cells 
in PD has hardly been explored. NK cells are active members of the innate immune system 
that act as a first-line defence, and also mediate between the innate and adaptive immune 
systems (Salazar-Mather et al., 1996; Su et al., 2001). Interestingly, a recent study using blood 
samples from PD patiens indicates that the NK activity increases as the disease advances 
(Mihara et al., 2008). Moreover, the study also showed that the NK cell content among the 
total lymphocytes of the PD group was higher than in the control group (Mihara et al., 
2008). 
7. Prospects for Syn-based immunotherapy in PD 
In addition to its well known importance in the pathogenesis of PD, Syn is becoming a 
primary target for preventing or controlling the process of PD. In the late few years, 
vaccination for treating some neurodegenerative disorders has emerged as a potentially 
useful approach. Thus far, this avenue has been scarcely explored for PD. Importantly, 
immunization with Syn was shown to generate a humoral response in a mouse model of 
PD (Masliah et al., 2005), producing beneficial albeit modest results on histopathological 
markers of the disease. On the contrary, using N-Syn as the immunogen proved to elicit 
strong antigen-specific effector T cell responses in MPTP-intoxicated mice that caused 
exacerbated neuroinflammation and neurodegeneration (Benner et al., 2008). This response 
was further shown to be largely mediated by Th17 cells and causing Treg dysfunction 
(Reynolds et al., 2010). In addition, the authors demonstrated that Treg cells from mice 
treated with the neuropeptide VIP, known to promote Treg responses (Delgado et al., 2005; 
Gonzalez-Rey et al., 2006), can efficiently modulate N-Syn-generated immunity in MPTP 
mice and confer neuroprotection (Reynolds et al., 2010), suggesting a possible novel 
therapeutic avenue for PD. 
Given that microglial activation can maintain or even aggravate the disease process, 
blocking inflammation or shifting the balance between pro-inflammatory and anti-
inflammatory states in a controlled manner, offers one of the most promising strategies 
for developing palliative (and maybe preventive) therapies for PD and related disorders. 
Epidemiological data have identified the non steroidal anti-inflammatory drug (NSAID) 
ibuprofen as neuroprotective for PD (Klegeris et al., 2007b). NSAIDs are thought to act on 
dopamine quinone formation and activation by Syn of both astrocytes and microglia. On 
the other hand, Gendelman and colleagues demonstrated that T cells from mice 
immunized with Copolymer-1 (Cop-1), are able to attenuate microglial responses and lead 
to neuroprotection in a MPTP mouse model of PD (Benner et al., 2004). This 
neuroprotective effect was later found to be mediated by the CD4+ type of T cells, 
suggesting the possible involvement of Treg cells (Laurie et al., 2007). Later work by the 
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same group confirmed this hypothesis by showing that passive transfer to MPTP mice of 
activated Treg cells, but not effector T cells, efficiently suppressed microglial activation 
and afforded neuroprotection (Reynolds et al., 2007), suggesting that the 
immunomodulating abilities of Treg cells could potentially be utilized as a therapeutic 
approach against PD (Stone et al., 2009). 
 
Fig. 1. Links between Syn and the immune response in PD. Continuous arrows with filled 
tips: positive effect; continuous arrows with open tips: cell transformation; discontinuous 
arrows: secretion of cellular factors. APC, Antigen-processing cell; BBB, Blood-brain barrier; 
CKs, Chemokines; IL, Interleukin; IFN-, Interferon ; LB, Lewy bodies; ROS, Reactive 
oxygen species; RNS, Reactive nitrogen species; TGF-, Tumor growth factor 
8. Conclusion 
It is well established that PD onset and progression are characterized by sustained activation of 
microglia, linked to significant dopaminergic neuron loss in the SN of the brain. Over the last 
few years, it has become accepted that overexpression and aggregation of Syn, an amyloid-like 
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protein, is linked to neurotoxicity through various proposed mechanisms, and may be one of 
the primary causes of the immunological abnormalities observed in PD. Recent studies with 
cellular and in vivo models of the disease indicate that increased levels of extracellular Syn, 
both in its aggregated and non-aggregated forms, are found in a PD scenario.  
Accumulated evidence has now established that aggregated extracellular Syn is able to 
trigger the activation of microglia, inducing a highly detrimental cascade of 
neuroinflammation and neuronal demise. In addition, recent studies have have 
demonstrated that non-aggregated Syn can also have a substantial impact on microglial 
phenotype and cytokine release profile, especially in the cases of familial PD Syn mutants. 
By releasing toxic factors, or by phagocytosing neighbouring cells, activated microglia and 
astrocytes are believed to form a self-perpetuating neuronal degeneration cycle. On the 
other hand, recent findings point at a possible role of the adaptive immune system involving 
Syn, and the pathological process in PD. Clearly, further studies in this direction are 
necessary to help understand the complex immunological mechanisms underlying PD and 
the key, and possibly multiple, links between Syn and the immune response in relation to 
in relation to pathogenesis (Figure 1). 
In addition to trying to develop effective tools to prevent Syn aggregation, modulating the 
innate immune response by intervening microglial activation, promoting a selective aSyn-
specific humoral response, and manipulating the balance between effector and 
immunomodulatory T-cell populations, may be considered as highly promising therapeutic 
approaches for the treatment of PD and other synucleinopathies. 
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